Bristlecone Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

Bristlecone Advisors, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$402.49 - $513.76 $40,249 - $51,376	100 Added 4.65%	2,250 $1.09 Million
Q2 2024 Jul 25, 2024	SELL	$392.81 - $485.53 $5,892 - $7,282	-15 Reduced 0.69%	2,150 $1.01 Million
Q1 2024 Apr 22, 2024	BUY	$407.69 - $446.08 $46,884 - $51,299	115 Added 5.61%	2,165 $904,000
Q4 2023 Jan 25, 2024	BUY	$343.0 - $410.68 $1,715 - $2,053	5 Added 0.24%	2,050 $834,000
Q3 2023 Oct 16, 2023	SELL	$338.18 - $362.46 $18,938 - $20,297	-56 Reduced 2.67%	2,045 $711,000
Q2 2023 Aug 03, 2023	SELL	$314.42 - $351.91 $18,236 - $20,410	-58 Reduced 2.69%	2,101 $739,000
Q1 2023 May 11, 2023	SELL	$283.23 - $323.1 $92,332 - $105,330	-326 Reduced 13.12%	2,159 $680,000
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $14,573 - $16,395	-51 Reduced 2.01%	2,485 $717,000
Q3 2022 Oct 27, 2022	SELL	$273.83 - $305.53 $7,941 - $8,860	-29 Reduced 1.13%	2,536 $734,000
Q2 2022 Jul 25, 2022	BUY	$234.96 - $292.55 $70,957 - $88,350	302 Added 13.35%	2,565 $723,000
Q1 2022 Apr 22, 2022	BUY	$221.42 - $260.97 $5,314 - $6,263	24 Added 1.07%	2,263 $591,000
Q4 2021 Jan 19, 2022	BUY	$177.01 - $223.45 $48,500 - $61,225	274 Added 13.94%	2,239 $492,000
Q3 2021 Oct 19, 2021	BUY	$181.39 - $202.99 $74,369 - $83,225	410 Added 26.37%	1,965 $356,000
Q2 2021 Jul 21, 2021	BUY	$187.49 - $221.1 $3,937 - $4,643	21 Added 1.37%	1,555 $314,000
Q1 2021 Apr 30, 2021	BUY	$207.02 - $241.31 $35,400 - $41,264	171 Added 12.55%	1,534 $330,000
Q4 2020 Jan 25, 2021	BUY	$207.01 - $276.09 $282,154 - $376,310	1,363 New	1,363 $322,000

1,810

239M

1.95M

1.14M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $101B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Bristlecone Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Bristlecone Advisors, LLC with notifications on news.